New Antibiotics for Drug-Resistant Bacterial Infections
Official title: Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections
Funded at State University of New York at Buffalo · NIH-11129737 · Data updated 2026-11-12
This project is creating new antibiotics called biamyxins to fight serious infections caused by drug-resistant bacteria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $793,943 |
| NIH project number | 5R01AI182297-02 |
| Project ID | NIH-11129737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with severe, multidrug-resistant Gram-negative bacterial infections, particularly those caused by Acinetobacter baumannii, Enterobacteriaceae, or Pseudomonas aeruginosa, could potentially benefit from this research.
✕Less likely to help
Patients with infections caused by bacteria that are not Gram-negative or are not multidrug-resistant would likely not receive direct benefit from this specific antibiotic approach.
What this research studies
Many severe infections in hospitals are caused by Gram-negative bacteria that are becoming resistant to current medicines, making them very hard to treat. This is a major health concern worldwide, as existing antibiotics are often ineffective against these tough pathogens. Our team is developing a new type of antibiotic, called biamyxins, which are designed to specifically target and bind to the outer layer of these resistant bacteria. These new medicines aim to overcome the resistance that makes other treatments ineffective, offering a fresh approach to combat these dangerous infections.
Why it matters
Potential benefit: If successful, these new biamyxin antibiotics could offer a much-needed treatment option for patients suffering from life-threatening, multidrug-resistant bacterial infections.
How similar studies have gone: This project describes a new class of antibiotics, biamyxins, suggesting a novel approach to combat drug-resistant Gram-negative bacteria.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Zhao, Yanan — State University of New York at Buffalo
- Study coordinator: Zhao, Yanan
Related research
Other NIH-funded projects on the same topics.
-
Host-Directed Orynotide for MDR Gram-Negative Infections
A new drug candidate called Orynotide MTD12813 is being developed to treat serious drug-resistant infections caused by bacteria like Acinetobacter and Enterobacteriaceae.
-
Genomic-informed, low-cost, portable test to rapidly identify drug-resistant bacterial infections
A portable, affordable test called BADLOCK could quickly identify bacteria and resistance genes from blood samples to help treat drug-resistant infections.
-
Novel BMX antibiotics for tough Gram-negative infections
A new class of BMX antibiotics is being developed to fight hard-to-treat Gram-negative infections like Acinetobacter baumannii in patients.
-
Center to speed up antibacterial drugs for hard-to-treat infections
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
PACC1 in the body’s defense against bacterial infections and sepsis
A study exploring how a protein called PACC1 helps immune cells fight bacteria and prevent sepsis, with potential benefits for people at risk of severe infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.